Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma
Open Access
- 9 September 2021
- journal article
- letter
- Published by Ovid Technologies (Wolters Kluwer Health) in Chinese Medical Journal
- Vol. 135 (2), 250-252
- https://doi.org/10.1097/cm9.0000000000001695
Abstract
An abstract is unavailable. This article is available as a PDF only.Keywords
This publication has 5 references indexed in Scilit:
- A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant‐ineligible multiple myelomaBritish Journal of Haematology, 2018
- Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World ExperienceActa Haematologica, 2017
- Multiple myeloma: patient outcomes in real‐world practiceBritish Journal of Haematology, 2016
- Clinical Pharmacokinetics and Pharmacodynamics of LenalidomideClinical Pharmacokinetics, 2016
- Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myelomaInternational Journal of Hematology, 2010